New chemoradiotherapy combinations in head and neck cancer

Giuseppina Busto, Renzo Corvò, Isabella Ricci, Giuseppe Sanguineti, Marco Benasso

Research output: Contribution to journalArticlepeer-review


Head and neck squamous cell cancer is the sixth most common cancer worldwide. Surgical management is effective as a single modality only for early-stage cancers (30% of patients). Making progress in this cancer is of vital interest. The standard treatment for advanced disease is chemoradiotherapy, with the goal of palliation of symptoms and prolongation of life. Response rates to even the best of regimens are approximately 30-40%, with the median survival period of approximately 6 months. Various approaches to treatment of recurrent disease are under investigation, including new drugs or combinations of drugs, with radiotherapy.

Original languageEnglish
Pages (from-to)111-115
Number of pages5
JournalExpert Review of Anticancer Therapy
Issue number1
Publication statusPublished - 2001


  • 5-Fluorouracil
  • Chemoradiotherapy
  • Cisplatin
  • Gemcitabine
  • Head and neck squamous cell cancer
  • Irinotecan
  • Taxanes

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology


Dive into the research topics of 'New chemoradiotherapy combinations in head and neck cancer'. Together they form a unique fingerprint.

Cite this